Increasing Investment by Pharmaceutical Companies and Favorable Government Policies has Propelled the Growth of the Monoclonal Antibodies Market in the North America Region!

The increased adoption of monoclonal antibodies and rise in the incidence of cancer in U.S. is one of the major factor propelling the growth of the monoclonal antibodies market in the region. According to the American Cancer Society, “Cancer and Figures 2022”, there was an estimated 1.9 million new cancer cases diagnosed in 2022. Moreover, as per the same source in 2020, the most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the U.S. Thus, the increasing cases of cancer require taregted treatment which is expected to increase the demand for monoclonal antibodies over the forecast period. Apart from this, the presence of major key players and rising investments by pharmaceutical companies are also propelling the regional market growth.

Further, the North America Monoclonal Antibodies Market is expected to grow at a strong CAGR of 8.5% during the forecast period (2022-2028). North America held a significant share of the market in 2021. Several factors such as increasing healthcare expenditure, the surge in the prevalence of chronic diseases, rising patient awareness, and the presence of the majority of key players and their associated surge in research and development activities are driving the regional market. For instance, in February 2022, Eli Lilly and Company announced that U.S. FDA has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant. Bebtelovimab is a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2.

Request For Sample PDF- https://univdatos.com/report/monoclonal-antibodies-market/get-a-free-sample-form.php?product_id=36128

Based on source, the market is segmented into chimeric, human, humanized, and murine. The humanized antibodies are anticipated to grow with significant CAGR during the forecast period owing to their widespread use for a wide range of target antigens, such as cancer cells, or immunosuppressor and immunomodulatory molecules. Demand for such antibodies is also supported by their lower immunogenicity as compared to chimeric mAbs.
For a detailed analysis of the Global Monoclonal Antibodies Market browse through– https://univdatos.com/report/monoclonal-antibodies-market/

By indication, the market is categorized into oncology, autoimmune diseases, infectious diseases, inflammatory diseases, and others. The oncology segment held the dominant share of the market in 2021 owing to rise in the prevalence of cancer. Apart from this, rising product approvals and increasing adoption due to their targeted nature is also having a positive impact on the growth of the segment. For instance, in February 2023, U.S. FDA granted approval to Jemperli for adult patients with mismatch repair–deficient (dMMR), recurrent or advanced endometrial cancer.

Global Monoclonal Antibodies Market Segmentation

Market Insight, by Source

• Chimeric
• Human
• Humanized
• Murine

Market Insights, by Indication

• Oncology
• Autoimmune Disorders
• Infectious Diseases
• Inflammatory Diseases
• Others

Market Insights, by End User

• Hospital
• Speciality Centers
• Others

Market Insight, by Region

• North America
  • U.S.
  • Canada
  • Rest of North America
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• APAC
  • China
  • Japan
  • India
  • South Korea
  • Rest of APAC
• Rest of the World

Top Company Profiles

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd
• Amgen Inc.
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Bayer AG
• AstraZeneca
• Sanofi
• Merck & Co., Inc.,
• Johnson & Johnson Private Limited